The next evolution of Continuous Biomarker Monitoring

Continuous Glucose Monitoring (CGM) has reshaped diabetes management and catalysed a multibillion-dollar global market. Yet CGM is just the first phase of a broader shift towards Continuous Biomarker Monitoring (CBM), where multiple physiological and biochemical analytes are tracked dynamically on fused-data platforms.

The global CGM market was valued at USD 12.4B in 2025 and is projected to reach USD 47.1B by 2034. This growth reflects strong demand for real-time data, expanded reimbursement, and broader application across both clinical and consumer health domains.

However, as glucose-focused markets mature, growth is starting to plateau in regions with high adoption. Commercial differentiation will increasingly come from multi-biomarker sensing, supported by advanced data fusion and expansion into adjacent clinical markets such as cardiovascular disease, chronic kidney disease, and pain management. In these areas, many conditions still rely on periodic diagnostics and could benefit from a continuous approach.

CBM should leverage core principles of CGM – including electrochemical sensing combined with continuous data transmission – but expand the impact to create rich, contextualised data ecosystems capable of improving patient outcomes and healthcare economics. This white paper outlines clinical opportunities, commercial rationale, technical considerations, and the strategic implications of transitioning from CGM to broader CBM ecosystems.

In this white paper we discuss:

Enhancing diabetes management with CBM
Applying CGM principles to cardiovascular disease
Reimaging chronic pain management
Setting a CBM system up for success

Fill out the form to download the whitepaper